GO
Loading...

Bristol-Myers Squibb Co

More

  • Final Glance: Pharmaceuticals companies Wednesday, 10 Sep 2014 | 6:16 PM ET

    Baxter International Inc. rose $1.01 or 1.4 percent, to $75.28. Bristol-Myers Squibb Co. rose$. 60 or 1.2 percent, to $51.08. Hospira rose$. 14 or. 3 percent, to $53.15.

  • Midday Glance: Pharmaceuticals companies Wednesday, 10 Sep 2014 | 1:21 PM ET

    Baxter International Inc. rose$. 84 or 1.1 percent, to $75.11. Bristol-Myers Squibb Co. rose$. 70 or 1.4 percent, to $51.18. Johnson& Johnson rose $1.10 or 1.1 percent, to $104.90.

  • Early Glance: Pharmaceuticals companies Wednesday, 10 Sep 2014 | 10:32 AM ET

    Baxter International Inc. rose$. 44 or. 6 percent, to $74.71. Bristol-Myers Squibb Co. rose$. 27 or. 5 percent, to $50.75. Johnson& Johnson rose$. 41 or. 4 percent, to $104.21.

  • Final Glance: Pharmaceuticals companies Tuesday, 9 Sep 2014 | 8:15 PM ET

    Baxter International Inc. rose$. 05 or. 1 percent, to $74.27. Bristol-Myers Squibb Co. fell$. 71 or 1.4 percent, to $50.48. Hospira rose$. 29 or. 6 percent, to $53.01.

  • Midday Glance: Pharmaceuticals companies Tuesday, 9 Sep 2014 | 1:22 PM ET

    Baxter International Inc. rose$. 12 or. 2 percent, to $74.34. Bristol-Myers Squibb Co. fell$. 46 or. 9 percent, to $50.73. Hospira rose$. 29 or. 6 percent, to $53.01.

  • Early Glance: Pharmaceuticals companies Tuesday, 9 Sep 2014 | 10:26 AM ET

    Baxter International Inc. rose$. 04 or. 1 percent, to $74.26. Bristol-Myers Squibb Co. fell$. 47 or. 9 percent, to $50.72. Hospira rose$. 01 or percent, to $52.73.

  • Final Glance: Pharmaceuticals companies Monday, 8 Sep 2014 | 6:38 PM ET

    Baxter International Inc. rose$. 02 or percent, to $74.22. Bristol-Myers Squibb Co. rose$. 07 or. 1 percent, to $51.19. Hospira fell $1.18 or 2.2 percent, to $52.72.

  • Midday Glance: Pharmaceuticals companies Monday, 8 Sep 2014 | 1:36 PM ET

    Baxter International Inc. rose$. 40 or. 5 percent, to $74.60. Bristol-Myers Squibb Co. fell$. 01 or percent, to $51.11. Hospira fell$. 88 or 1.6 percent, to $53.02.

  • Early Glance: Pharmaceuticals companies Monday, 8 Sep 2014 | 10:34 AM ET

    Baxter International Inc. rose$. 06 or. 1 percent, to $74.26. Bristol-Myers Squibb Co. rose$. 02 or percent, to $51.14. Hospira fell $1.22 or 2.3 percent, to $52.68.

  • *Novartis's LCZ696 and PCSK9 drugs could treat millions. Hopes have spiked for a heart failure drug from Novartis and an innovative class of injectable anti-cholesterol agents known as PCSK9 inhibitors after the release of data at the ESC's annual meeting indicated that they can save more lives than standard therapies.

  • *AstraZeneca shares up 2 percent. LONDON, Aug 29- Hopes for AstraZeneca's promising cancer drug pipeline were boosted on Friday by news the company had moved its immuno-oncology medicine MEDI-4736 into a mid-stage study in colorectal cancer.

  • Aug 26- Pfizer Inc said Tuesday it will test its Xalkori lung cancer drug with Merck& Co's experimental immunotherapy pembrolizumab, in hopes the combination will improve the outcomes for patients taking the approved Pfizer therapy. The largest U.S. drugmakers said the combination study will begin in 2015 and be conducted by Pfizer.

  • LOS ANGELES, Aug 25- U.S. regulators are likely to approve Merck& Co's highly anticipated immuno-oncology drug, pembrolizumab, as a treatment for melanoma well ahead of a late October deadline, according to three sources familiar with the situation.

  • Diversified U.S. manufacturer 3 M Co and medical equipment makers CareFusion Corp and C.R. Bard Inc are among the companies exploring a potential deal for ConvaTec, the people said. CareFusion, with a market capitalization of $9 billion, and C.R. Bard, with $11.2 billion, would both be able to achieve an inversion if they use their own stock to pay for ConvaTec.

  • The R&D elite: America's most innovative companies Wednesday, 6 Aug 2014 | 6:00 AM ET

    The CNBC RQ 50 identifies companies that don't just spend big on R&D, but spend right, creating return on innovation for shareholders.

  • Why dying kids can't get the drugs they need Tuesday, 5 Aug 2014 | 7:33 AM ET
    Nathalie Traller back in the clinic.

    Terminally ill patients are increasingly seeking access experimental drugs outside clinical trials, but drug companies often decline these requests. A look at why.

  • AstraZeneca steps up push into cancer immunotherapy Thursday, 31 Jul 2014 | 8:51 AM ET

    LONDON, July 31- AstraZeneca is accelerating its push into cancer immunotherapy, with plans to test a key experimental drug in new tumor types. AstraZeneca said it would present further data looking at MEDI4736 in lung cancer, as well as early results for head and neck cancer, in September at the annual meeting of the European Society for Medical Oncology.

  • Pfizer beats forecasts as oncology drugs grow Tuesday, 29 Jul 2014 | 10:54 AM ET

    Pfizer reported higher-than-expected second-quarter earnings, helped by growing sales of its cancer medicines.

  • Pfizer's need for deal looms with earnings report Monday, 28 Jul 2014 | 7:12 AM ET

    Pfizer's vulnerability to cheap generics and its weak roster of experimental medicines will be on display Tuesday, when the company reports earnings.

  • NEW YORK, July 28- Pfizer Inc's vulnerability to cheaper generics and its weak roster of experimental medicines will be on display Tuesday when the company reports quarterly earnings, reviving interest in its pursuit of AstraZeneca Plc or other deals to fortify its pipeline.